Stay updated on Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page.
Latest updates to the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision: v3.3.3 has been added to the page history, and the 'HHS Vulnerability Disclosure' item along with the 'Revision: v3.3.2' entry were removed.SummaryDifference0.2%
- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedThe Record History now includes a new revision entry for v3.3.2 and removes v3.2.0.SummaryDifference0.1%
- Check54 days agoChange DetectedDeleted a non-critical notice banner about government funding and operating status across the page, and this does not affect core content, trial details, or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%
- Check68 days agoChange DetectedVersion history shows no substantive changes to the study record; the Changes field states 'None (earliest version on record)'. The page layout remains unchanged.SummaryDifference0.1%
- Check97 days agoChange DetectedUpdated operating-status notice and version 3.2.0; removed version 3.1.0.SummaryDifference13%
- Check104 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.3%
Stay in the know with updates to Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page.